Sibutramine & naloxone: Infra-additive interaction in the regulation of appetite?

Behavioural Brain Research

Volumn 207, Issue 1, 2010, Pages 174-181

  Tallett, A J ^a   Blundell, J E ^a   Rodgers, R J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Appetite; Behavioural satiety sequence; Food intake; Monotherapy; Naloxone; Polytherapy; Rats; Sibutramine; Weight gain

Indexed keywords

NALOXONE; SIBUTRAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL FOOD; ANOREXIA; APPETITE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEEDING BEHAVIOR; FOOD INTAKE; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; SATIETY; SINGLE DRUG DOSE; WEIGHT GAIN;

ANALYSIS OF VARIANCE; ANIMALS; APPETITE; APPETITE DEPRESSANTS; BEHAVIOR, ANIMAL; BODY WEIGHT; CYCLOBUTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EATING; FEEDING BEHAVIOR; MALE; NALOXONE; NARCOTIC ANTAGONISTS; RATS; TIME FACTORS;

EID: 70649091995     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.10.004     Document Type: Article

References (77)

1. Adan R.A.H., Vanderschuren L.J.M.J., and la Fleur S.E. Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci 29 (2008) 208-217
2. Aronne L.J., and Thornton-Jones Z.D. New targets for obesity pharmacotherapy. Clin Pharmacol Ther 81 (2007) 748-752
3. Arterburn D.E., Crane P.K., and Veenstra D.L. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Int Med 164 (2004) 994-1003
4. Bays H., and Dujovne C. Anti-obesity drug development. Exp Opin Investig Drugs 11 (2002) 1189-1204
5. Beczkowska I.W., and Bodnar R.J. Naloxone and serotonin receptor subtype antagonists: interactive effects upon deprivation-induced intake. Pharmacol Biochem Behav 38 (1991) 605-610
6. Berendsen H.H.G., and Broekkamp C.L.E. A peripheral 5-HT1D-like receptor involved in serotonergic induced hindlimb scratching in rats. Eur J Pharmacol 194 (1991) 201-208
7. Berendsen H.H.G., Broekkamp C.L.E., and van Delft A.M.L. Possible involvement of 5HT1D receptors in drug-induced hindlimb scratching in rats. European Eur J Pharmacol 183 (1990) 1924-2925
8. Bhavsar S., Watkins J., and Young A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 81 (2004) 781-793
9. Bray G.A., and Greenway F.L. Pharmacological treatment of the overweight patient. Pharmacol Rev 59 (2007) 151-184
10. Casado A., Rodriguez V.M., Portillo M.P., Macarulla M.T., Abecia L.C., Echevarria E., et al. Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins. Nutr Neurosci 6 (2003) 103-111
11. Chen R.Z., Huang R-RC, Shen C.-Y., MacNeil D.J., and Fong T.M. Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Res 999 (2004) 227-230
12. Chiesi M., Huppertz C., and Hofbauer K.G. Pharmacotherapy of obesity: targets and perspectives. Trends Pharmacol Sci 22 (2001) 247-254
13. Clapham J.C., Arch J.R.S., and Tadayyon M. Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmac Ther 89 (2001) 81-121
14. Collins P., and Williams G. Drug treatment of obesity: from past failures to future successes?. Br J Clin Pharmac 51 (2001) 13-25
15. Connoley I.P., Liu Y.-L., Frost I., Reckless I.P., Heal D.J., and Stock M.J. Thermogenic effects of sibutramine and its metabolites. Brit J Pharmacol 126 (1999) 1487-1495
16. Cooper S.J., Jackson A., Morgan R., and Carter R. Evidence for opiate receptor involvement in the consumption of a high palatability diet in nondeprived rats. Neuropeptides 5 (1985) 345-348
17. Eison A.S., Wright R.N., and Freeman R. Peripheral 5-carboxamidotryptamine induces hindlimb scratching by stimulating 5-HT1A receptors in rats. Life Sci 51 (1992) 95-99
18. Fernandez-Tome M.P., Gonzalez Y., and Del Rio J. Interaction between opioid agonists or naloxone and 5-HTP on feeding behavior in food-deprived rats. Pharmacol Biochem Behav 29 (1988) 387-392
19. Foltin R.W., Woolverton W.L., and Schuster C.R. The effect of d-amphetamine and haloperidol alone and in combination on milk drinking in rats. Psychopharmacology 80 (1983) 342-344
20. Gardell L.R., Whalen C.A., Chattophadyay S., Cavallaro C.A., Hubbell C.L., and Reid L.D. Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage. Alcoholism: Clin Exp Res 21 (1997) 1435-1439
21. Glass M.J., Grace M.K., Cleary J.P., Billington C.J., and Levine A.S. Potency of naloxone's anorectic effect in rats is dependent on diet preference. Am J Physiol Regulatory Integrative Comp Physiol 271 (1996) R217-R221
22. Glass M.J., Jhaveri R.M., and Smith L.R. Comparison of potency and duration of action of nalmefene and naloxone. Anesth Analg 78 (1994) 536-541
23. Greenway F.L., Whitehouse M.J., Guttadauria M., Anderson J.W., Atkinson R.L., Fujioka K., et al. Rational design of a combination medication for the treatment of obesity. Obesity 17 (2009) 30-39
24. Grignaschi G., Fanelli E., Scagnol I., and Samanin R. Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats. Brit J Pharmacol 127 (1999) 1190-1194
25. Hagan M.M., Holguin F.D., Cabello C.E., Hanscom D.R., and Moss D.E. Combined naloxone and fluoxetine on deprivation-induced binge-eating of palatable foods in rats. Pharmacol Biochem Behav 58 (1997) 1103-1107
26. Halford J.C.G., Cooper G.D., Dovey T.M., Ishii Y., Rodgers J., and Blundell J.E. The psychopharmacology of appetite: targets for potential anti-obesity agents. Curr Med Chem: CNS Agents 3 (2003) 283-310
27. Halford J.C.G., Heal D.J., and Blundell J.E. Effects in the rat of sibutramine on food intake and the behavioural satiety sequence. Brit J Pharmacol 114 (1995) 387P
28. Halford J.C.G., Wanninayake S.C.D., and Blundell J.E. Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 61 (1998) 159-168
29. Holtzman S.G. Behavioral effects of separate and combined administration of naloxone and d-amphetamine. J Pharmacol Exp Ther 189 (1974) 51-60
30. Holtzman S.G. Suppression of appetitive behavior in the rat by naloxone: lack of effect of prior morphine dependence. Life Sci 24 (1979) 219-226
31. Ishii Y., Blundell J.E., Halford J.C.G., and Rodgers R.J. Effects of systematic variation in presatiation and fasting on the behavioural satiety sequence in male rats. Physiol Behav 79 (2003) 227-238
32. Jackson H.C., Needham A.M., Hutchins L.J., Mazurkiewicz S.E., and Heal D.J. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Brit J Pharmacol 121 (1997) 1758-1762
33. Johnson B.A., Ait-Daoud N., and Prihoda T.J. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypothesis to preliminary clinical evidence. Alchoholism: Clin Exp Res 24 (2000) 737-742
34. Kaya A., Aydin N., Topsever O., Filiz M., Ozturk A., Dagar A., et al. Efficacy of sibutramine, orlistat and combination therapy pn short-term weight management in obese patients. Biomed Pharmacother 58 (2004) 582-587
35. Kirkham T.C., and Blundell J.E. Dual action of naloxone on feeding revealed by behavioural analysis: separate effects on initiation and termination of eating. Appetite 5 (1984) 45-52
36. Kirkham T.C., and Williams C.M. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology 153 (2001) 267-270
37. Kuraishi Y., Yageta Y., Konno M., Andoh T., Yamaguchi-Miyamoto T., and Nojima H. Intracisternal, but not intrathecal, injection of naloxone inhibits cutaneous itch-related response in mice. Biol Pharmaceut Bull 31 (2008) 2143-2145
38. 3 receptor antagonists in the regulation of alcohol intake. Alcohol Alcoholism Supplements 2 (1994) 545-549
39. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforsch 3 (1953) 285-290
40. Luque C.A., and Rey J.A. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 440 (2002) 119-128
41. Marks-Kaufman R., and Kanarek R.B. Modifications of nutrient selection induced by naloxone in rats. Psychopharmacology 74 (1981) 321-324
42. Nagi S.H., Berkowitz B.A., Yang J.C., Hempstead J., and Spector S. Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology 44 (1976) 398-410
43. McNeely W., and Goa K.L. Sibutramine. A review of its contribution to the management of obesity. Drugs 56 (1998) 1093-1124
44. National Audit Office 2001. Tackling obesity in England. Auditor General, HMSO, Norwich, UK National Audit Office.
45. 7-36 inhibit food intake additively. Endocrinology 146 (2005) 5120-5127
46. NIH Obesity Research Task Force 2004. http://www.obesityresearch.nih.gov.
47. Nisoli E., and Carruba M.O. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obesity Revs 1 (2000) 127-139
48. Padwal R.S., Li S.K., and Lau D.C.W. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomozed control trials. Int J Obesity 27 (2003) 1437-1446
49. Padwal R.S., and Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine and rimonabant. Lancet 369 (2007) 71-77
50. Rennie K.L., and Jebb S.A. Prevalence of obesity in Great Britain. Obesity Revs 6 (2005) 11-12
51. Rezvani A., Overstreet D., Mason G., Janowsky D., Kamedi M., Clarke E.J., et al. Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. Alchohol Alcoholism 35 (2000) 76-83
52. [3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology 148 (2007) 6054-6061
53. Roth J.D., and Rowland N.E. Anorectic efficacy of the fenfluramine/phenteramine combination in rats: additivity or synergy. Eur J Pharmacol 373 (1999) 127-134
54. Roth J.D., Trevaskis J.L., Wilson J., Lei C., Athanacio J., Mack C., et al. Antiobesity effects of the beta-cell hormone amylin in combination with phenteramine or sibutramine in diety-induced obese rats. Int J Obesity 32 (2008) 1201-1210
55. Rowland N.E., Mukherjee M., and Robertson K. Effects of the cannabinoid receptor antagonist SR141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 159 (2001) 111-116
56. Sanger D.J., and McCarthy P.S. A comparison of the effects of opiate antagonists on operant and ingestive behavior. Pharmacol Biochem Beav 16 (1982) 1013-1015
57. Sanger D.J., McCarthy P.S., and Metcalf G. The effects of opiate antagonists on food intake are stereospecific. Neuropharmacology 20 (1981) 45-47
58. Schwartz M.W., Woods S.C., Porte D., Seeley R.J., and Baskin D.G. Central nervous control of food intake. Nature 404 (2000) 661-671
59. Strack A.M., Shu J., Camacho R., Gorski J.N., Murphy B., MacIntyre D.E., et al. Regulation of body weight and carcass composition by sibutramine in rats. Obesity Res 10 (2002) 173-181
60. Stricker-Kongrad A., Souquet A.M., and Burlet C. Effects of sibutramine on feeding behaviour in dietary-induced nduced obesity: role of dietary constituents. Int J Obes 19 145 (1995) P398
61. Tallett A.J., Blundell J.E., and Rodgers R.J. Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology 195 (2007) 27-39
62. Tallett A.J., Blundell J.E., and Rodgers R.J. Acute anorectic response to cannabinoid receptor antagonist/inverse agonist AM 251 in rat: indirect behavioural mediation. Behav Pharmacol 18 (2007) 591-600
63. Tallett A.J., Blundell J.E., and Rodgers R.J. Behaviourally-selective hypophagic effects of naloxone in non-deprived male rats presented with palatable food. Behav Brain Res 187 (2008) 417-427
64. Tallett A.J., Blundell J.E., and Rodgers R.J. Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching. Physiol Behav 94 (2008) 422-431
65. Tallett A.J., Blundell J.E., and Rodgers R.J. Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats. Pharmacol Biochem Behav 91 (2009) 358-366
66. Tallett A.J., Blundell J.E., and Rodgers R.J. Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats. Behav Brain Res 198 (2009) 359-365
67. Tallett A.J., Blundell J.E., and Rodgers R.J. Night & day: diurnal differences in the behavioural satiety sequence in male rats. Physiol Behav 97 (2009) 125-130
68. 3-36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 (2005) 3748-3756
69. Thavanathan R., and Volkoff H. Effects of amylin on feeding of goldfish: interactions with CCK. Regulat Peptides 133 (2006) 90-96
70. Vemuri V.K., Janero D.R., and Makriyannis A. Therapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav 93 (2008) 671-686
71. Wellman P.J., Tow S., and McMahon L. Isobolographic assessment of the effects of combinations of phenylpropanolamine and fenfluramine on food intake in rats. Pharamcol Biochem Behav 50 (1995) 287-291
72. Weiss S.M. Pharmacological and behavioural examination of the defensive reactions of laboratory mice to the calls of the Tawny owl. PhD thesis, 1995, School of Psychology, University of Leeds.
73. 3) receptor antagonist reduce experimentally-induced itch. Inflamm Res 46 (1997) 412-416
74. Wessinger W.D. Approaches to the study of drug interactions in behavioral pharmacology. Neurosci Biobehav Revs 10 (1986) 103-113
75. World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO Technical Report Series No. 84, 2000; ISBN 92 4 120894 5.
76. Yamaguchi T., Nagasawa T., Satoh M., and Kuraishi Y. Itch-associated response induced by intradermal serotonin through 5-HT2 receptors in mice. Neurosci Res 35 (1999) 77-83
77. Zink R.W., Rohrbach K., and Froehlich J.C. Naltrexone and fluoxetine act synergistically to decrease alcohol intake. Alcoholism: Clin Exp Res 21 (1997) 104A